TTrialPathMatch Me to Trials
← Back to trials
RecruitingAlport Syndrome, X-LinkedAlport Syndrome, Autosomal Recessive

EXACT Study: A Blinded Study in Patients With Alport Syndrome to Evaluate Exaluren Efficacy and Safety

Eligible age

12+ yrs

Accepts

All genders

Locations

6 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This is a randomized, double-Blind, placebo-controlled study to evaluate the efficacy and safety of exaluren in Alport Syndrome patients with nonsense mutations in COL4A3/4/5 genes. Targeted 24 patients aged 12 and older will be enrolled in the trial. The study will be comprised of the following periods for each participant: * a Screening period of up to 6 weeks (42 days) * a total Treatment Period of exaluren 0.75 mg/kg or placebo administered daily subcutaneously for 32 weeks: Part 1: patients are randomized to either exaluren or placebo for 16 weeks. Part 2: all patients across both randomized arms receive exaluren for 16 additional weeks. * a safety/efficacy Follow-up Period of 4 weeks after the last treatment

Sponsor: Eloxx Pharmaceuticals, Inc.

You may qualify if…

  • ✓ A confirmed diagnosis of X-linked or autosomal recessive Alport Syndrome with a documented nonsense mutation of COL4A5 in a male or nonsense mutation of COL4A3 or COL4A4 (male or female)
  • ✓ eGFR\>40 ml/min/1.73 m2
  • ✓ Urinary protein based on two spot urine collections \[urine protein/creatinine ratio (UPCR) ≥ 300 mg/g\]
  • ✓ Stable regimen of ACEi/ARB for at least 12 weeks before Day 1

You may not qualify if…

  • ✕ History of any organ transplantation
  • ✕ Liver disease characterized by cirrhosis or portal hypertension. Participants with alanine aminotransferase (ALT), aspartate aminotransferase (AST), and/or a total bilirubin 1.5 times the upper limit of normal (ULN) will be excluded
  • ✕ History of dialysis
  • ✕ Acute kidney injury within 4 weeks before screening
  • ✕ Active dizziness

Where it's recruiting

California

Los Angeles · Stanford

Colorado

Denver

Minnesota

Minneapolis

New Jersey

Hackensack

Pennsylvania

Philadelphia

Texas

San Antonio

Source: ClinicalTrials.gov · NCT07523581 · last updated 2026-09-30